News|Articles|May 19, 2021

EMA Recommends Change in Storage Conditions for Pfizer/BioNTech Vaccine

The agency’s human medicines committee has recommended extending the approved storage period of unopened thawed vials at 2–8 0C from five days to 31 days.

The European Medicines Agency (EMA) announced on May 17, 2021 that its human medicines committee (CHMP) has recommended changing the approved storage conditions for Pfizer/BioNTech’s COVID-19 vaccine, Comirnaty. The recommendation extends the approved storage period of the unopened thawed vial at 2–8 oC from five days to 31 days.

The change follows EMA’s assessment of additional stability data, and the agency expects it to have an impact on planning and logistics for the rollout of the vaccine to member states in the European Union. The change will be implemented in updated product labeling.

Source: EMA


Related to this article

Regulatory Roundup—September 2026
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Pharma Logistician Using IoT Based On Blockchain | Image Credit: ©leowolfert -stock.adobe.com
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.